|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide derived from the N-terminal region of the human C35 protein (chromosome 17 open reading frame 37 (C17orf37 protein), XTP4).|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS, pH 7.4|
|Contains||0.1% sodium azide|
|Tested Applications||Dilution *|
|Western Blot (WB)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
During the past decade, the role of the ERBB2(neu/HER2) oncogene as an important predictor of patient outcome and response to various therapies in breast cancer has been clearly established. The C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer. Identification of shared tumor-specific targets is useful in developing broadly applicable therapies. The C35 gene is located on chromosome 17q12, 505nucleotides from the 3' end of the ERBB2oncogene, the antigenic target for trastuzumab(Herceptin) therapy. The chromosomal arrangement of the genes encoding C35 andERBB2 is tail to tail. The ORF 37 open reading frame encodes a 12-kDa protein of unknown function.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.